RHEUMATOLOGISTS HAVE PLENTY OF CHOICE AMONG BIOLOGIC AGENTS FOR RA – WHERE WILL ACTEMRA FIND ITS NICHE?

NEW STUDY BY BIOTRENDS HIGHLIGHTS CHANGES IN THE MANAGEMENT OF GOUT AND HYPERURICEMIA AMONG RHEUMATOLOGISTS AND PRIMARY CARE PHYSICIANS

STELARA IMPRESSES WITH EFFICACY DATA AND DOSING CONVENIENCE, BUT SAFETY CONCERNS LIKELY TO IMPACT NEAR TERM UPTAKE

Use of AMAG’s Feraheme is on the Rise with 23% of Nephrologists Reporting Use of the Product

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Page 1 of 12